High levels of debt obligations have led several biotechnology and pharmaceutical companies into financial distress, requiring them to file for bankruptcy and, in many cases, seek sales of their ...

The U.S. Food and Drug Administration (FDA) is currently conducting an on-site inspection of Samsung Biologics Co.'s ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Following President Trump's Most Favored Nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Cell division is an essential biological process that removes aged cells and continuously renews tissues. In the human body, billions of cells divide each day: intestinal cells are completely renewed ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...